Simcere inks license agreement with Roche for SIM0660

Simcere Zaiming, a subsidiary of China’s Simcere Pharmaceutical Group (2096:HK) has entered into an exclusive global licensing agreement with Swiss pharma giant Roche (ROG: SIX) for the development and commercialization of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.

SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release.